Updated treatment options for immune thrombocytopenia
Intern Med J
.
2024 Feb;54(2):201-203.
doi: 10.1111/imj.16246.
Epub 2023 Nov 17.
Authors
Philip Choi
1
2
,
Eileen Merriman
3
,
Ashwini Bennett
4
5
,
Anoop Enjeti
6
7
8
,
Chee Wee Tan
9
,
Isaac Goncalves
10
11
,
Danny Hsu
12
13
,
Robert Bird
14
Affiliations
1
The Canberra Hospital, Canberra, Australian Capital Territory, Australia.
2
John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia.
3
North Shore Hospital, Auckland, New Zealand.
4
Monash Health, Melbourne, Victoria, Australia.
5
Monash University, Melbourne, Victoria, Australia.
6
Calvary Mater, Newcastle, New South Wales, Australia.
7
University of Newcastle, Newcastle, New South Wales, Australia.
8
NSW Health Pathology, Newcastle, New South Wales, Australia.
9
Royal Adelaide Hospital, Adelaide, South Australia, Australia.
10
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
11
Royal Melbourne Hospital, Melbourne, Victoria, Australia.
12
Liverpool Hospital, Sydney, New South Wales, Australia.
13
University of New South Wales, Kensington, New South Wales, Australia.
14
Princess Alexandria Hospital, Brisbane, Queensland, Australia.
PMID:
37975334
DOI:
10.1111/imj.16246
No abstract available
Publication types
Editorial
MeSH terms
Humans
Purpura, Thrombocytopenic, Idiopathic* / diagnosis
Purpura, Thrombocytopenic, Idiopathic* / drug therapy
Thrombocytopenia*